<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "2: pharmaceutical", fill: "#49796b"},
{source: "2: pharmaceutical", target: "2: competitive", fill: "#49796b"},
{source: "2: competitive", target: "2: competition across", fill: "#49796b"},
{source: "2: competition across", target: "2: activities", fill: "#49796b"},
{source: "2: pharmaceutical", target: "3: successfully", fill: "#8e4585"},
{source: "3: successfully", target: "3: profitability", fill: "#8e4585"},
{source: "3: profitability", target: "3: flows could", fill: "#8e4585"},
{source: "3: flows could", target: "3: adversely affected", fill: "#8e4585"},
{source: "3: successfully", target: "4: competitors", fill: "#872657"},
{source: "4: competitors", target: "4: generic manufacturers", fill: "#872657"},
{source: "4: generic manufacturers", target: "4: pharmaceuticals especially", fill: "#872657"},
{source: "4: competitors", target: "13: generic competition", fill: "#01796f"},
{source: "13: generic competition", target: "13: branded products generally reduces", fill: "#01796f"},
{source: "13: branded products generally reduces", target: "13: adversely", fill: "#01796f"},
{source: "13: adversely", target: "13: profitability", fill: "#01796f"},
{source: "13: profitability", target: "13: cash flows", fill: "#01796f"},
{source: "13: generic competition", target: "24: patent infringement suit", fill: "#b31b1b"},
{source: "24: patent infringement suit", target: "24: federal district court", fill: "#b31b1b"},
{source: "24: federal district court", target: "24: company seeking", fill: "#b31b1b"},
{source: "24: company seeking", target: "24: patent rights", fill: "#b31b1b"},
{source: "24: patent infringement suit", target: "25: discovery", fill: "#355e3b"},
{source: "25: discovery", target: "25: appeals process", fill: "#355e3b"},
{source: "25: appeals process", target: "25: such suits", fill: "#355e3b"},
{source: "25: such suits", target: "25: several years", fill: "#355e3b"},
{source: "25: discovery", target: "33: additional versions", fill: "#9f1d35"},
{source: "33: additional versions", target: "33: products enter", fill: "#9f1d35"},
{source: "33: products enter", target: "33: generally lose market", fill: "#9f1d35"},
{source: "33: generally lose market", target: "33: margins on", fill: "#9f1d35"},
{source: "33: margins on", target: "33: product decline", fill: "#9f1d35"},
{source: "33: additional versions", target: "37: exclusivity", fill: "#a0d6b4"},
{source: "37: exclusivity", target: "37: December ", fill: "#a0d6b4"},
{source: "37: exclusivity", target: "48: Further the Federal Circuit ", fill: "#a4c639"},
{source: "48: Further the Federal Circuit ", target: "48: new opinion on", fill: "#a4c639"},
{source: "48: new opinion on", target: "48: February ", fill: "#a4c639"},
{source: "48: February ", target: "48: District Court ", fill: "#a4c639"},
{source: "48: District Court ", target: "48: consideration", fill: "#a4c639"},
{source: "48: consideration", target: "48: the Purdue ", fill: "#a4c639"},
{source: "48: Further the Federal Circuit ", target: "49: ultimately unsuccessful", fill: "#9bddff"},
{source: "49: ultimately unsuccessful", target: "49: common stock may decline", fill: "#9bddff"},
{source: "49: ultimately unsuccessful", target: "61: strategies may increase", fill: "#3cb371"},
{source: "61: strategies may increase", target: "61: risks associated with", fill: "#3cb371"},
{source: "61: risks associated with", target: "61: generic products", fill: "#3cb371"},
{source: "61: generic products", target: "61: prevent such", fill: "#3cb371"},
{source: "61: prevent such", target: "61: introduction altogether", fill: "#3cb371"},
{source: "61: strategies may increase", target: "62: entered into", fill: "#51484f"},
{source: "62: entered into", target: "62: tax sharing agreement with", fill: "#51484f"},
{source: "62: tax sharing agreement with", target: "62: Endo Pharma LLC in July ", fill: "#51484f"},
{source: "62: Endo Pharma LLC in July ", target: "62: may continue", fill: "#51484f"},
{source: "62: may continue", target: "62: cash payments", fill: "#51484f"},
{source: "62: cash payments", target: "62: liability company", fill: "#51484f"},
{source: "62: liability company", target: "62: significant", fill: "#51484f"},
{source: "62: significant", target: "62: common stock", fill: "#51484f"},
{source: "62: common stock", target: "62: which affiliates", fill: "#51484f"},
{source: "62: which affiliates", target: "62: management", fill: "#51484f"},
{source: "62: entered into", target: "63: connection with", fill: "#c3b091"},
{source: "63: connection with", target: "63: acquisition", fill: "#c3b091"},
{source: "63: acquisition", target: "63: stock option", fill: "#c3b091"},
{source: "63: stock option", target: "63: diluted only", fill: "#c3b091"},
{source: "63: diluted only", target: "63: common stock", fill: "#c3b091"},
{source: "63: common stock", target: "63: such shares prior", fill: "#c3b091"},
{source: "63: such shares prior", target: "63: merger with", fill: "#c3b091"},
{source: "63: connection with", target: "64: only currently outstanding shares", fill: "#ff0028"},
{source: "64: only currently outstanding shares", target: "64: Endo Pharma LLC ", fill: "#ff0028"},
{source: "64: Endo Pharma LLC ", target: "64: such options", fill: "#ff0028"},
{source: "64: such options", target: "64: upon exercise", fill: "#ff0028"},
{source: "64: only currently outstanding shares", target: "67: no obligation", fill: "#f984e5"},
{source: "67: no obligation", target: "67: payments under", fill: "#f984e5"},
{source: "67: payments under", target: "67: tax sharing agreement", fill: "#f984e5"},
{source: "67: tax sharing agreement", target: "67: liquidity event", fill: "#f984e5"},
{source: "67: no obligation", target: "START_HERE", fill: "#f984e5"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Application Software</td>
    </tr>
    <tr>
      <td>Automobile Manufacturers</td>
    </tr>
    <tr>
      <td>Motorcycle Manufacturers</td>
    </tr>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
    <tr>
      <td>Independent Power Producers and Energy Traders</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Crime</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Rights</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Military</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Host meeting</td>
    </tr>
    <tr>
      <td>Psychological state</td>
    </tr>
    <tr>
      <td>Request</td>
    </tr>
    <tr>
      <td>Yield position</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
    <tr>
      <td>Reward</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Pharmaceutical_industry">Pharmaceutical industry</a></td>
      <td>The pharmaceutical industry discovers, develops, produces, and markets drugs or pharmaceutical drugs for use as medications to be administered to patients (or self-administered), with the aim to cure them, vaccinate them, or alleviate symptoms.  Pharmaceutical companies may deal in generic or brand medications and medical devices.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Competition">Competition</a></td>
      <td>Competition is a rivalry where two or more parties strive for a common goal which cannot be shared: where one's gain is the other's loss (an example of which is a zero-sum game). Competition can arise between entities such as organisms, individuals, economic and social groups, etc.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Profit_(economics)">Profit (economics)</a></td>
      <td>An economic profit is the difference between the revenue a  commercial entity has received from its outputs and the opportunity costs of its inputs. It equals to total revenue minus total cost, including both explicit and implicit costs.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Profitability_index">Profitability index</a></td>
      <td>Profitability index (PI), also known as profit investment ratio (PIR) and value investment ratio (VIR), is the ratio of payoff to investment of a proposed project. It is a useful tool for ranking projects because it allows you to quantify the amount of value created per unit of investment.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Profitable_growth">Profitable growth</a></td>
      <td>Profitable Growth is the combination of profitability and growth, more precisely the combination of Economic Profitability and Growth of Free cash flows. Profitable growth is aimed at seducing the financial community; it emerged in the early 80s when shareholder value creation became firms’ main objective.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Customer_profitability">Customer profitability</a></td>
      <td>Customer profitability (CP) is the profit the firm makes from serving a customer or customer group over a specified period of time, specifically the difference between the revenues earned from and the costs associated with the customer relationship in a specified period. According to Philip Kotler,"a profitable customer is a person, household or a company that overtime, yields a revenue stream that exceeds by an acceptable amount the company's cost stream of attracting, selling and servicing the customer."\nCalculating customer profit is an important step in understanding which customer relationships are better than others.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Return_on_equity">Return on equity</a></td>
      <td>The return on equity (ROE) is a measure of the profitability of a business in relation to the equity. Because shareholder's equity can be calculated by taking all assets and subtracting all liabilities, ROE can also be thought of as a return on assets minus liabilities.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Competitor_analysis">Competitor analysis</a></td>
      <td>Competitive analysis in marketing and strategic management is an assessment of the strengths and weaknesses of current and potential competitors. This analysis provides both an offensive and defensive strategic context to identify opportunities and threats.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Drug_Price_Competition_and_Patent_Term_Restoration_Act">Drug Price Competition and Patent Term Restoration Act</a></td>
      <td>The Drug Price Competition and Patent Term Restoration Act (Public Law 98-417), informally known as the Hatch-Waxman Act, is a 1984 United States federal law that encourages the manufacture of generic drugs by the pharmaceutical industry and established the modern system of government generic drug regulation in the United States. Representative Henry Waxman of California and Senator Orrin Hatch of Utah sponsored the act.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/United_States_District_Court_for_the_Central_District_of_California">United States District Court for the Central District of California</a></td>
      <td>The United States District Court for the Central District of California (in case citations, C.D. Cal.; commonly referred to as the CDCA or CACD) is a Federal trial court that serves over 19 million people in Southern and Central California, making it the most populous federal judicial district. The district was created on September 18, 1966.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/United_States_District_Court_for_the_District_of_Columbia">United States District Court for the District of Columbia</a></td>
      <td>The United States District Court for the District of Columbia (in case citations, D.D.C.) is a federal district court in the District of Columbia. It also occasionally handles (jointly with the United States District Court for the District of Hawaii and the High Court of American Samoa) federal issues that arise in the territory of American Samoa, which has no local federal court or territorial court.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/United_States_Court_of_Appeals_for_the_District_of_Columbia_Circuit">United States Court of Appeals for the District of Columbia Circuit</a></td>
      <td>The United States Court of Appeals for the District of Columbia Circuit (in case citations, D.C. Cir.) is one of the thirteen United States Courts of Appeals. It has the smallest geographical jurisdiction of any of the U.S. federal appellate courts, and covers only one district court: the U.S. District Court for the District of Columbia.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Stock_market">Stock market</a></td>
      <td>A stock market, equity market, or share market is the aggregation of buyers and sellers of stocks (also called shares), which represent ownership claims on businesses; these may include securities listed on a public stock exchange, as well as stock that is only traded privately, such as shares of private companies which are sold to investors through equity crowdfunding platforms. Investment is usually made with an investment strategy in mind.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/December">December</a></td>
      <td>December is the twelfth and the final month of the year in the Julian and Gregorian calendars. It is also the last of seven months to have a length of 31 days.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/December_1924_German_federal_election">December 1924 German federal election</a></td>
      <td>Federal elections were held in Germany on 7 December 1924, the second that year after the Reichstag had been dissolved on 20 October. The Social Democratic Party remained the largest party in the Reichstag, receiving an increased share of the vote and winning 131 of the 493 seats.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/December_10">December 10</a></td>
      <td>December 10 is the 344th day of the year (345th in leap years) in the Gregorian calendar;  21 days remain until the end of the year.\n\n\n== Events ==\n\n\n=== Pre-1600 ===\n1317 – The "Nyköping Banquet": King Birger of Sweden treacherously seizes his two brothers Valdemar, Duke of Finland and Eric, Duke of Södermanland, who were subsequently starved to death in the dungeon of Nyköping Castle.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/December_31">December 31</a></td>
      <td>December 3 is the 337th day of the year (338th in leap years) in the Gregorian calendar;  28 days remain until the end of the year.\n\n\n== Events ==\n\n\n=== Pre-1600 ===\n915 – Pope John X crowns Berengar I of Italy as Holy Roman Emperor (probable date).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/December_1">December 1</a></td>
      <td>December is the twelfth and the final month of the year in the Julian and Gregorian calendars. It is also the last of seven months to have a length of 31 days.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/December_8">December 8</a></td>
      <td>December 3 is the 337th day of the year (338th in leap years) in the Gregorian calendar;  28 days remain until the end of the year.\n\n\n== Events ==\n\n\n=== Pre-1600 ===\n915 – Pope John X crowns Berengar I of Italy as Holy Roman Emperor (probable date).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Public_opinion">Public opinion</a></td>
      <td>Public opinion is the collective opinion on a specific topic or voting intention relevant to a society. It is the people's views on matters affecting them.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/New_York_Stock_Exchange">New York Stock Exchange</a></td>
      <td>The New York Stock Exchange (NYSE, nicknamed "The Big Board") is an American stock exchange in the Financial District of Lower Manhattan in New York City. It is by far the world's largest stock exchange by market capitalization of its listed companies at US$30.1 trillion as of February 2018.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Options_strategy">Options strategy</a></td>
      <td>Option strategies are the simultaneous, and often mixed, buying or selling of one or more options that differ in one or more of the options' variables.  Call options, simply known as Calls, give the buyer a right to buy a particular stock at that option's strike price.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Johnson_&amp;_Johnson">Johnson &amp; Johnson</a></td>
      <td>Johnson &amp; Johnson (J&amp;J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Wyeth">Wyeth</a></td>
      <td>Wyeth, LLC was an American pharmaceutical company. The company was founded in Philadelphia, Pennsylvania, in 1860 as John Wyeth and Brother.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Kaye_Scholer">Kaye Scholer</a></td>
      <td>Kaye Scholer was a law firm founded in 1917 by Benjamin Kaye and Jacob Scholer. The firm had more than 450 attorneys in nine offices located in the cities of Chicago, Frankfurt, London, Los Angeles, New York City (headquarters), Shanghai, Palo Alto, Washington, D.C., and West Palm Beach.In late 2016, Kaye Scholer voted to merge with Washington D.C.-based law firm Arnold &amp; Porter to create a $1 billion+ sized multinational firm with a large offering both in the US and internationally.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Amantadine">Amantadine</a></td>
      <td>Amantadine, sold under the brand name Gocovri among others, is a medication used to treat dyskinesia associated with parkinsonism and influenza caused by type A influenzavirus, though its use for the latter is no longer recommended due to widespread drug resistance. It acts as a nicotinic antagonist, dopamine agonist, and noncompetitive NMDA antagonist.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Common_stock">Common stock</a></td>
      <td>Common stock is a form of corporate equity ownership, a type of security. The terms voting share and ordinary share are also used frequently outside of the United States.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Common_stock_dividend">Common stock dividend</a></td>
      <td>A common stock dividend is the dividend paid to common stock owners from the profits of the company.  Like other dividends, the payout is in the form of either cash or stock.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Matthiola_incana">Matthiola incana</a></td>
      <td>Matthiola incana is a species of flowering plant in the cabbage family Brassicaceae. Common names include Brompton stock, common stock, hoary stock, ten-week stock, and gilly-flower.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Convertible_bond">Convertible bond</a></td>
      <td>In finance, a convertible bond or  convertible note or convertible debt (or a convertible debenture if it has a maturity of greater than 10 years) is a type of bond that the holder can convert into a specified number of shares of common stock in the issuing company or cash of equal value.  It is a hybrid security with debt- and equity-like features.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Class_B_share">Class B share</a></td>
      <td>In finance, a Class B share or Class C share is a designation for a share class of a common or preferred stock that typically has strengthened voting rights or other benefits compared to a Class A share that may have been created. The equity structure, or how many types of shares are offered, is determined by the corporate charter.B share can also refer to various terms relating to stock classes:\n\nB share (mainland China), a class of stock on the Shanghai and Shenzhen stock exchanges\nB share (NYSE), a class of stock on the New York Stock ExchangeMost of the time, Class B shares may have lower repayment priorities in the event a company declares bankruptcy.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Stock_option_expensing">Stock option expensing</a></td>
      <td>Stock option expensing is a method of accounting for the value of share options, distributed as incentives to employees, within the profit and loss reporting of a listed business.\nOn the income statement, balance sheet, and cash flow statement say that the loss from the exercise is accounted for by noting the difference between the market price (if one exists) of the shares and the cash received, the exercise price, for issuing those shares through the option.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Incentive_stock_option">Incentive stock option</a></td>
      <td>Incentive stock options (ISOs), are a type of employee stock option that can be granted only to employees and confer a U.S. tax benefit. ISOs are also sometimes referred to as statutory stock options by the IRS. ISOs have a strike price, which is the price a holder must pay to purchase one share of the stock.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Employee_stock_ownership">Employee stock ownership</a></td>
      <td>Employee stock ownership, or employee share ownership, is where a company's employees own shares in that company (or in the parent company of a group of companies). US Employees typically acquire shares through a share option plan.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Gene_Tools">Gene Tools</a></td>
      <td>Gene Tools, LLC is a limited liability company located in Philomath, Oregon, United States that manufactures Morpholino antisense oligos and delivery reagents. Gene Tools was founded in 1997 and began regularly shipping custom-sequence Morpholino oligos in 2000.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/At-the-market_offering">At-the-market offering</a></td>
      <td>An at-the-market (ATM) offering is a type of follow-on offering of stock utilized by publicly traded companies in order to raise capital over time. In an ATM offering, exchange-listed companies incrementally sell newly issued shares or shares they already own into the secondary trading market through a designated broker-dealer at prevailing market prices.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Injection_(economics)">Injection (economics)</a></td>
      <td>When a central bank makes a short-term loan to a member institution, it is said to be injecting liquidity. In the United States, the Federal Reserve maintains a target federal funds rate for banks to loan money overnight to each other.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Liquidity_risk">Liquidity risk</a></td>
      <td>Liquidity risk is a financial risk that for a certain period of time a given financial asset, security or commodity cannot be traded quickly enough in the market without impacting the market price.\n\n\n== Types ==\nMarket liquidity – An asset cannot be sold due to lack of liquidity in the market – essentially a sub-set of market risk.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>ENDO PHARMACEUTICALS HOLDINGS INC      Item 1A Risk Factors                              Risks Related to Our Business          We <font color="blue"><font color="blue">face intense</font> <font color="blue">competition</font></font>, in <font color="blue">particular from companies</font> that develop rival     products to our <font color="blue"><font color="blue">branded product</font>s</font> and <font color="blue">from companies with which</font> we compete to     acquire rights to <font color="blue"><font color="blue">intellectual</font> property assets</font></td>
    </tr>
    <tr>
      <td>The  <font color="blue">pharmaceutical</font>  industry  is  intensely  <font color="blue">competitive</font>, and we face     <font color="blue"><font color="blue">competition</font> across</font> the full range of our <font color="blue">activities</font></td>
    </tr>
    <tr>
      <td>If we fail to compete     <font color="blue">successfully</font> in any of these areas, our business, <font color="blue">profitability</font> and cash     <font color="blue">flows could</font> be <font color="blue"><font color="blue">adversely</font> affected</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">competitors</font> include many of the major     brand name and <font color="blue">generic <font color="blue">manufacturers</font></font> of <font color="blue">pharmaceutical</font>s, especially those     doing  business  in  the  United  States</td>
    </tr>
    <tr>
      <td>In  the  market for branded     <font color="blue">pharmaceutical</font> products, our <font color="blue">competitors</font>, including Abbott Laboratories,     Alpharma Inc, Johnson &amp; Johnson, Ligand Pharmaceuticals Incorporated,     Pfizer, Inc</td>
    </tr>
    <tr>
      <td>and The Purdue Frederick Company, <font color="blue">vary depending on product</font>     category, <font color="blue">dosage strength</font> and drug-delivery systems</td>
    </tr>
    <tr>
      <td>In addition to product     safety, development and efficacy, other <font color="blue">competitive</font> factors in the branded     <font color="blue">pharmaceutical</font> market include <font color="blue">product quality</font> and price, reputation, service     and access to scientific and technical information</td>
    </tr>
    <tr>
      <td>It is possible that     <font color="blue">developments by</font> our <font color="blue">competitors</font> will make our products or <font color="blue">technologies</font>     un<font color="blue">competitive</font> or obsolete</td>
    </tr>
    <tr>
      <td>Because we are <font color="blue">smaller than</font> many of our national     <font color="blue">competitors</font> in the branded <font color="blue">pharmaceutical</font> products sector, we may lack the     financial and other resources needed to maintain our <font color="blue">profit margins</font> and     market share in this sector</td>
    </tr>
    <tr>
      <td>The intensely <font color="blue">competitive</font> environment of the <font color="blue"><font color="blue">branded product</font>s</font> business     requires  an  ongoing,  extensive search for medical and <font color="blue">technological</font>     <font color="blue">innovations</font> and the ability to <font color="blue">market products effectively</font>, including the     ability  to communicate the effectiveness, safety and value of branded     products to <font color="blue">healthcare professionals</font> in <font color="blue">private practice</font>, group practices     and <font color="blue">managed care organizations</font></td>
    </tr>
    <tr>
      <td>Our  branded  <font color="blue">products face <font color="blue"><font color="blue">competition</font> from</font> <font color="blue"><font color="blue">generic version</font>s</font></font></td>
    </tr>
    <tr>
      <td><font color="blue">Generic     </font>versions are <font color="blue"><font color="blue">generally</font> <font color="blue">significant</font>ly cheaper than</font> the branded version, and,     where available, may be required or encouraged in preference to the branded     version  under  third  <font color="blue">party reimbursement programs</font>, or <font color="blue">substituted by</font>     pharmacies for <font color="blue">branded versions by law</font></td>
    </tr>
    <tr>
      <td>The entrance of <font color="blue">generic <font color="blue">competition</font></font>     to our <font color="blue"><font color="blue">branded product</font>s</font> <font color="blue">generally</font> reduces our market share and <font color="blue">adversely</font>     affects our <font color="blue">profitability</font> and <font color="blue">cash flows</font></td>
    </tr>
    <tr>
      <td>Generic <font color="blue"><font color="blue">competition</font> with</font> our     <font color="blue"><font color="blue">branded product</font>s</font>, including Percocet^^®^, has had and <font color="blue">will continue</font> to have     a material adverse effect on the net sales and <font color="blue">profitability</font> of our branded     products</td>
    </tr>
    <tr>
      <td>Additionally, we compete to acquire the <font color="blue"><font color="blue">intellectual</font> property assets</font> that we     require to continue to develop and broaden our <font color="blue">product range</font></td>
    </tr>
    <tr>
      <td>In addition to     our in-house research and <font color="blue">development efforts</font>, we seek to acquire rights to     new   <font color="blue">intellectual</font>  property  through  corporate  <font color="blue"><font color="blue">acquisition</font>s</font>,  asset     <font color="blue"><font color="blue">acquisition</font>s</font>, licensing and <font color="blue">joint venture <font color="blue">arrangements</font></font></td>
    </tr>
    <tr>
      <td><font color="blue">Competitors </font>with     <font color="blue">greater resources may</font> acquire assets that we seek, and even where we are     successful, <font color="blue">competition</font> may increase the <font color="blue"><font color="blue">acquisition</font> price</font> of such assets or     prevent  us  from  <font color="blue">capitalizing</font>  on  such  <font color="blue"><font color="blue">acquisition</font>s</font>  or  licensing     <font color="blue">opportunities</font></td>
    </tr>
    <tr>
      <td>If  we fail to compete <font color="blue">successfully</font>, our <font color="blue">growth may</font> be     limited</td>
    </tr>
    <tr>
      <td>If <font color="blue">generic <font color="blue">manufacturers</font></font> use <font color="blue">litigation</font> and <font color="blue">regulatory</font> means to obtain     approval for <font color="blue"><font color="blue">generic version</font>s</font> of our <font color="blue"><font color="blue">branded drug</font>s</font>, our <font color="blue">sales may suffer</font></td>
    </tr>
    <tr>
      <td><font color="blue">The <font color="blue">Hatch Waxman Act </font></font>permits the FDA to approve ANDAs for <font color="blue"><font color="blue">generic version</font>s</font>     of <font color="blue"><font color="blue">branded drug</font>s</font></td>
    </tr>
    <tr>
      <td>The ANDA <font color="blue">process permits competitor companies</font> to obtain     <font color="blue">marketing approval</font> for a drug with the <font color="blue">same active</font> ingredient for the same     uses but does not require the conduct and submission of <font color="blue">clinical studies</font>     <font color="blue">demonstrating</font>  safety  and efficacy for that product</td>
    </tr>
    <tr>
      <td>In place of such     <font color="blue">clinical studies</font>, an ANDA <font color="blue">applicant essentially</font> needs only to submit data     <font color="blue">demonstrating</font> that its product is <font color="blue">bioequivalent</font> to the <font color="blue">branded product</font></td>
    </tr>
    <tr>
      <td><font color="blue">The <font color="blue">Hatch Waxman Act </font></font>requires an applicant for a drug that relies, at least     in part, <font color="blue">on data from</font> the <font color="blue">branded drug</font> regarding the safety and efficacy of     the <font color="blue">same active</font> ingredient, to <font color="blue">notify us</font> of their <font color="blue">application</font> and potential     <font color="blue">infringement</font> of our <font color="blue">patent rights</font></td>
    </tr>
    <tr>
      <td>Upon receipt of this notice we would have     45 days  to bring a patent <font color="blue">infringement</font> suit in <font color="blue">federal district court</font>     against the <font color="blue">company seeking</font> to violate our <font color="blue">patent rights</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">discovery</font>,     trial and <font color="blue">appeals process</font> in <font color="blue">such suits</font> can take <font color="blue">several years</font></td>
    </tr>
    <tr>
      <td>If such a     suit is commenced, the <font color="blue">Hatch Waxman Act </font>provides a 30-month stay on the     approval of the competitor’s <font color="blue">application</font></td>
    </tr>
    <tr>
      <td>If the <font color="blue">litigation</font> is resolved in     favor of the <font color="blue">generic applicant</font> or the <font color="blue">challenged patent expires during</font> the     30-month  stay  period, the stay is lifted and the FDA’s review of the     <font color="blue">application</font> may be completed</td>
    </tr>
    <tr>
      <td>Such <font color="blue">litigation</font> is often time-consuming and     <font color="blue">quite costly</font> and may result in <font color="blue">generic <font color="blue">competition</font></font> if such patent(s) are not     upheld or if the <font color="blue">generic competitor</font> does not infringe such patent(s)</td>
    </tr>
    <tr>
      <td>The     filing of any ANDA in respect to any of our <font color="blue"><font color="blue">branded drug</font>s</font>, particularly     Lidoderm^^®^, could have an adverse impact on our stock price and, if the     patents covering our <font color="blue"><font color="blue">branded drug</font>s</font>, including Lidoderm^^®^, were not upheld     in <font color="blue">litigation</font> or if the <font color="blue">generic competitor</font> is found to not infringe these     patents, the resulting <font color="blue">generic <font color="blue">competition</font></font> would have a material adverse     effect on our net sales, gross profit, operating income, net income and cash     flows</td>
    </tr>
    <tr>
      <td>We <font color="blue"><font color="blue">face intense</font> <font color="blue">competition</font></font> from other <font color="blue">manufacturers</font> of <font color="blue"><font color="blue">generic version</font>s</font> of     our <font color="blue">generic products</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">generic products</font> compete with <font color="blue"><font color="blue">branded product</font>s</font> and with <font color="blue"><font color="blue">generic version</font>s</font>     made  by or for other <font color="blue">manufacturers</font>, such as Mallinckrodt Inc, Roxane     Laboratories, Inc,  Teva  Pharmaceutical  Industries Ltd</td>
    </tr>
    <tr>
      <td>When  <font color="blue"><font color="blue">additional</font> versions</font> of one of our generic     <font color="blue">products enter</font> the market, we <font color="blue"><font color="blue">generally</font> <font color="blue">lose market</font></font> share and our selling     prices and <font color="blue">margins on</font> the <font color="blue">product decline</font></td>
    </tr>
    <tr>
      <td>Because we are <font color="blue">smaller than</font> many     of our full-line <font color="blue">competitors</font> in the generic <font color="blue">pharmaceutical</font> products sector,     we may lack the financial and other resources needed to maintain our profit     margins and market share in this sector</td>
    </tr>
    <tr>
      <td>25     ______________________________________________________________________    [50]Table of <font color="blue">Contents       </font>On June 7, 2005, we launched the 10mg, 20mg, 40mg and 80mg strengths of our     <font color="blue">bioequivalent</font>  versions of OxyContin^^®^</td>
    </tr>
    <tr>
      <td>We had 180 days of marketing     <font color="blue"><font color="blue">exclusivity</font> under</font> the <font color="blue">Hatch Waxman Act </font><font color="blue">with respect</font> to the 10mg, 20mg and     40mg strengths of this product, since we were the <font color="blue">first applicant</font> to file an     ANDA containing a <font color="blue">Paragraph IV </font><font color="blue">certification</font> for these <font color="blue">oxycodone extended</font>     <font color="blue">release strengths</font></td>
    </tr>
    <tr>
      <td>After the expiration of our marketing <font color="blue">exclusivity</font> period     on <font color="blue">December </font>5, 2005, several <font color="blue">competitors</font> launched <font color="blue">bioequivalent</font> versions of     the 10mg, 20mg and 40mg strengths of OxyContin^^®^</td>
    </tr>
    <tr>
      <td>Other <font color="blue">competitors</font> may     launch <font color="blue">additional</font> <font color="blue"><font color="blue">generic version</font>s</font> of all <font color="blue">four strengths</font> of OxyContin^^®^</td>
    </tr>
    <tr>
      <td>The entrance of other <font color="blue">competitors</font> has and <font color="blue">will continue</font> to reduce our market     share for <font color="blue">bioequivalent</font> versions of OxyContin^^®^ and <font color="blue">adversely</font> affect the     <font color="blue">profitability</font> of these products</td>
    </tr>
    <tr>
      <td>Net sales of Lidoderm^^®^, generic <font color="blue">oxycodone extended</font> release, Percocet^^®^,     Endocet^^®^, and generic morphine sulfate accounted for: 51prca, 14prca, 13prca, 8prca     and 5prca; 50prca, 0prca, 14prca, 19prca and 10prca; and 30prca, 0prca, 36prca, 11prca and 16prca of our net     sales for the years ended <font color="blue">December </font>31, 2005, 2004 and 2003, respectively</td>
    </tr>
    <tr>
      <td>The FDA has granted Lidoderm^^®^ <font color="blue">orphan drug status</font> for the treatment of the     pain associated with post herpetic neuralgia, which means, <font color="blue">generally</font>, that     no other <font color="blue">lidocaine containing product</font> can be approved for this <font color="blue">indication</font>     prior to March 19, 2006</td>
    </tr>
    <tr>
      <td>On June 7, 2005, we launched our <font color="blue">generic extended</font>     release  oxycodone  product, our <font color="blue">bioequivalent</font>, or generic, version of     OxyContin^^®^</td>
    </tr>
    <tr>
      <td>After the expiration of our marketing <font color="blue">exclusivity</font> period in     <font color="blue">December </font>2005, several <font color="blue">competitors</font> launched <font color="blue">bioequivalent</font> versions of the     10mg, 20mg and 40mg strengths of OxyContin^^®^</td>
    </tr>
    <tr>
      <td>In addition, we could be     forced to stop selling our generic OxyContin^^®^ product if the District     Court or Federal Circuit <font color="blue">Court of Appeals </font>reverses their <font color="blue">decisions</font> in our     favor and one or more of <font color="blue">the Purdue </font>patents are found valid and enforceable     and there is a <font color="blue">final court decision adverse</font> to us</td>
    </tr>
    <tr>
      <td>See “—We <font color="blue">face intense</font>     <font color="blue"><font color="blue">competition</font> from</font> other <font color="blue">manufacturers</font> of <font color="blue"><font color="blue">generic version</font>s</font> of our generic     products</td>
    </tr>
    <tr>
      <td>” and “—Although we were successful in our <font color="blue">patent challenge against</font>     Purdue for our generic OxyContin^^®^ product, both at trial and on appeal,     the <font color="blue">Court of Appeals </font>has vacated its <font color="blue">unanimous affirmance</font> of the Opinion and     Order  in our favor and affirmed the <font color="blue">District Court</font>’s finding that, if     Purdue’s patents are enforceable, Endo’s <font color="blue">oxycodone extended</font>-release tablets     infringe these patents</td>
    </tr>
    <tr>
      <td>Further, the Federal Circuit issued a <font color="blue">new <font color="blue">opinion on</font></font>     <font color="blue">February </font>1, 2006 remanding the case to the same <font color="blue"><font color="blue">District Court</font> </font>for its     further <font color="blue">consideration</font> as to whether <font color="blue">the Purdue </font>patents are unenforceable</td>
    </tr>
    <tr>
      <td>If     we are <font color="blue">ultimately unsuccessful</font>, we may be liable for damages and the price     of our <font color="blue"><font color="blue">common stock</font> may decline</font></td>
    </tr>
    <tr>
      <td>”         If we were unable to continue to market any of these products, if any of     them were to <font color="blue">lose market</font> share, for example, as the result of the entry of     new <font color="blue">competitors</font>, particularly from <font color="blue"><font color="blue">generic version</font>s</font> of <font color="blue"><font color="blue">branded drug</font>s</font>, or if     the prices of any of these products were to <font color="blue">decline <font color="blue">significant</font>ly</font>, our net     sales, <font color="blue">profitability</font> and <font color="blue">cash flows</font> would be materially <font color="blue"><font color="blue">adversely</font> affected</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">introduction</font> of other <font color="blue">bioequivalent</font> versions of the 10mg, 20mg and 40mg     strengths of OxyContin^^®^ has had and <font color="blue">will continue</font> to have an adverse     effect  by  reducing  our  market  share  and  <font color="blue">adversely</font> affecting our     <font color="blue">profitability</font> and <font color="blue">cash flows</font> that we would have otherwise achieved if we     supplied  the  <font color="blue">exclusive generic equivalent</font> to the 10mg, 20mg and 40mg     strengths of OxyContin^^®^ and to MS Contin^^®^</td>
    </tr>
    <tr>
      <td>We <font color="blue"><font color="blue">face intense</font> <font color="blue">competition</font></font> from brand-name companies that sell or license     their own <font color="blue"><font color="blue">generic version</font>s</font> of our <font color="blue">generic products</font> or seek to delay the     <font color="blue">introduction</font> of <font color="blue">generic products</font></td>
    </tr>
    <tr>
      <td>Brand-name <font color="blue">pharmaceutical</font> companies have <font color="blue">taken aggressive</font> steps to thwart     <font color="blue">competition</font>  <font color="blue">from generic equivalents</font> of their brand-name products</td>
    </tr>
    <tr>
      <td>In     particular, brand-name companies <font color="blue">sell directly</font> to the <font color="blue">generics market</font> or     license their products for sale to the <font color="blue">generics market</font> through licensing     <font color="blue">arrangements</font> or strategic alliances with generic <font color="blue">pharmaceutical</font> companies     (so-called “<font color="blue">authorized generics</font>”)</td>
    </tr>
    <tr>
      <td>No <font color="blue">significant</font> <font color="blue">regulatory</font> approvals are     required for a brand-name manufacturer to <font color="blue">sell directly</font> or through a third     party to the <font color="blue">generic market</font></td>
    </tr>
    <tr>
      <td>Brand-name <font color="blue">manufacturers</font> do not face any other     <font color="blue"><font color="blue">significant</font> barriers</font> to <font color="blue">entry into such market</font></td>
    </tr>
    <tr>
      <td>to distribute the so-called “authorized generic”     versions of OxyContin^^®^ and MS Contin^^®^, the branded version of our     morphine  sulfate  extended  release  tablets, pursuant to one or more     <font color="blue">distribution</font> <font color="blue">arrangements</font> with Purdue</td>
    </tr>
    <tr>
      <td>The <font color="blue">introduction</font>s of these so-called     “<font color="blue">authorized generics</font>” have had and <font color="blue">may continue</font> to have an adverse effect by     reducing our market share and <font color="blue">adversely</font> affecting our <font color="blue">profitability</font> and cash     flows</td>
    </tr>
    <tr>
      <td>In addition, brand-name companies continually seek new ways to <font color="blue">delay generic</font>     <font color="blue">introduction</font> and decrease the impact of <font color="blue">generic <font color="blue">competition</font></font>, such as filing     <font color="blue">new patents on drugs whose original patent protection</font> is about to expire;     filing an increasing number of patents that are more complex and costly to     challenge; filing suits for patent <font color="blue">infringement</font> that <font color="blue">automatically delay</font>     <font color="blue">approval by</font> the FDA; developing <font color="blue">patented controlled release</font> or other next     generation products, which often reduces the demand for the <font color="blue">generic version</font>     of the <font color="blue">existing product</font> for which we may be seeking approval; changing     product  claims  and  product  labeling;  developing  and marketing as     over-the-counter products those <font color="blue"><font color="blue">branded product</font>s</font> that are about to face     <font color="blue">generic <font color="blue">competition</font></font>; or filing citizens’ petitions with the FDA seeking     <font color="blue">restraints on</font> our products or seeking to <font color="blue">prevent them from coming</font> to market</td>
    </tr>
    <tr>
      <td>These  <font color="blue">strategies may increase</font> the costs and <font color="blue">risks associated with</font> our     efforts  to  introduce  <font color="blue">generic products</font> and may delay or <font color="blue">prevent such</font>     <font color="blue">introduction</font> altogether</td>
    </tr>
    <tr>
      <td>26     ______________________________________________________________________    [51]Table of <font color="blue">Contents       </font>We <font color="blue">entered into</font> a <font color="blue">tax sharing <font color="blue">agreement</font> with</font> <font color="blue"><font color="blue">Endo Pharma LLC </font>in July </font>2000,     pursuant to which we have made and <font color="blue">may continue</font> to make large <font color="blue">cash payments</font>     to <font color="blue">Endo Pharma LLC </font>         Endo  Pharma LLC is a limited <font color="blue"><font color="blue">liability</font> company</font> that currently holds a     <font color="blue">significant</font> portion of our <font color="blue">common stock</font>, in <font color="blue">which affiliates</font> of Kelso &amp;     Company and certain members of <font color="blue">management</font> have an interest</td>
    </tr>
    <tr>
      <td><font color="blue">Endo Pharma LLC </font>    was  formed in <font color="blue">connection with</font> the <font color="blue">acquisition</font> of Algos Pharmaceutical     Corporation in July 2000 to ensure that the <font color="blue">stock option</font>s granted pursuant     to the <font color="blue">Endo Pharma LLC </font><font color="blue">stock option</font> plans <font color="blue">diluted only</font> the Endo <font color="blue">common stock</font>     held by persons and entities that held <font color="blue">such shares prior</font> to our <font color="blue">merger with</font>     Algos</td>
    </tr>
    <tr>
      <td>Upon the exercise of the <font color="blue">stock option</font>s <font color="blue">granted under</font> the Endo Pharma     LLC <font color="blue">stock option</font> plans, <font color="blue">only currently outstanding shares</font> of our common     stock held by <font color="blue">Endo Pharma LLC </font>will be received by holders of <font color="blue">such options</font>     <font color="blue">upon exercise</font></td>
    </tr>
    <tr>
      <td>Upon exercise of any of these <font color="blue">Endo Pharma LLC </font><font color="blue">stock option</font>s, we <font color="blue">generally</font>     will  be  permitted to <font color="blue">deduct as</font> a <font color="blue"><font color="blue">compensation</font> charge</font>, for income tax     purposes, an amount equal to the <font color="blue">difference between</font> the <font color="blue">market price</font> of our     <font color="blue">common stock</font> and the exercise price paid <font color="blue">upon exercise</font> of these options (as     of  <font color="blue">December </font>31,  2005,  we  had recognized <font color="blue"><font color="blue">compensation</font> <font color="blue">deductions</font></font> of     <font color="blue">approximately</font> dlra669 million, which is estimated to result in a tax benefit     amount of <font color="blue">approximately</font> dlra257 million)</td>
    </tr>
    <tr>
      <td>Because Endo Pharma LLC, and not us,     will provide the shares upon the exercise of the <font color="blue">stock option</font>s granted     pursuant to the <font color="blue">Endo Pharma LLC </font><font color="blue">stock option</font> plans, we <font color="blue">entered into</font> a tax     sharing <font color="blue">agreement</font> with <font color="blue">Endo Pharma LLC </font>under which we are required to pay to     <font color="blue">Endo Pharma LLC </font>upon the occurrence of a <font color="blue">liquidity event</font>, as described     further below, the amount of the <font color="blue">tax benefit <font color="blue">usable by us</font> as</font> a result of the     exercise of these <font color="blue">stock option</font>s into shares of our <font color="blue">common stock</font> held by <font color="blue">Endo     </font>Pharma LLC As of <font color="blue">December </font>31, 2005, <font color="blue">approximately</font> 32dtta7 million of these     <font color="blue">stock option</font>s had <font color="blue">been exercised into shares</font> of our <font color="blue">common stock</font> held by     <font color="blue">Endo Pharma LLC </font>Under the tax sharing <font color="blue">agreement</font>, we are required to pay     <font color="blue">approximately</font>  dlra257 million  to  Endo  Pharma LLC to the extent that a     <font color="blue"><font color="blue">compensation</font> charge</font> deduction is <font color="blue">usable by us</font> to reduce our taxes and based     upon  the  <font color="blue">assumption</font> that all other <font color="blue">deductions</font> of Endo are used prior     thereto</td>
    </tr>
    <tr>
      <td>We had <font color="blue">no obligation</font> to make any <font color="blue">payments under</font> the tax sharing <font color="blue">agreement</font> to     Endo  Pharma LLC prior to the occurrence of a <font color="blue">liquidity event</font></td>
    </tr>
    <tr>
      <td>The tax     sharing <font color="blue">agreement</font> defines a <font color="blue">liquidity event</font> as a <font color="blue">transaction</font> or series of     <font color="blue">transaction</font>s resulting in (a) a sale of greater than 20prca on a <font color="blue">fully diluted</font>     basis of our <font color="blue">common equity</font> (either through (i) <font color="blue">primary offerings by us</font>,     (ii) <font color="blue"><font color="blue">secondary sale</font>s</font> by <font color="blue">Endo Pharma LLC </font>or other holders of <font color="blue">common stock</font> or     (iii) a <font color="blue">combination</font> of <font color="blue">both such primary</font> and secondary offerings), (b) a     change in control of Endo or (c) a sale of all or <font color="blue">substantially</font> all of our     assets</td>
    </tr>
    <tr>
      <td>On April 30, 2004, we amended the tax sharing <font color="blue">agreement</font> to clarify     when a <font color="blue">liquidity event</font> has occurred and to provide for a <font color="blue">specific schedule</font>     <font color="blue">upon which payments currently</font> contemplated by the tax sharing <font color="blue">agreement</font>     would be made once a <font color="blue">liquidity event</font> has occurred</td>
    </tr>
    <tr>
      <td>The <font color="blue">amendment established</font>     a formula for <font color="blue">calculating</font> when a sale of 20prca of the <font color="blue">common equity</font> of <font color="blue">Endo     </font>had occurred and specified that <font color="blue"><font color="blue">secondary sale</font>s</font> of Endo <font color="blue">common stock</font> include     sales  pursuant  to a <font color="blue">shelf registration statement</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">amendment also</font>     provides that upon the occurrence of a <font color="blue">liquidity event</font>, we are obligated to     pay to Endo Pharma LLC, within 30 business days, the amount of the tax     benefits <font color="blue">usable by us</font> in each of the <font color="blue">previous <font color="blue">taxable years</font></font> for which we     have  filed a <font color="blue"><font color="blue">federal income</font> tax return</font></td>
    </tr>
    <tr>
      <td>Moreover, <font color="blue">with respect</font> to all     <font color="blue">taxable years</font> for which we file our <font color="blue"><font color="blue">federal income</font> tax return</font> after the     occurrence of a <font color="blue">liquidity event</font>, the amount of the tax benefits <font color="blue">usable by us</font>     in <font color="blue">each such year will</font> be paid to <font color="blue">Endo Pharma LLC </font>in two <font color="blue">installments</font>:     (i) 50prca of the estimated <font color="blue">amount shall</font> be paid within 15 business days of our     <font color="blue">receipt from</font> our <font color="blue"><font color="blue"><font color="blue">independent</font> registered public</font> <font color="blue">accounting firm</font></font> of an opinion     on our <font color="blue">final audited financial statements</font>, and (ii) the <font color="blue">remaining amount</font>     shall be paid within 30 business days of the filing of our <font color="blue">federal income</font>     tax return</td>
    </tr>
    <tr>
      <td>A <font color="blue">liquidity event</font> occurred on August 9, 2004, when <font color="blue">Endo Pharma LLC </font>completed     the <font color="blue">secondary sale</font> of 11 million shares of <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>The closing of this     offering, when <font color="blue">combined with</font> the sale by <font color="blue">Endo Pharma LLC </font>of the sale of     16dtta6 million shares on July 8, 2003, constituted a <font color="blue">liquidity event</font> under the     tax sharing <font color="blue">agreement</font> and triggered a payment obligation <font color="blue">with respect</font> to tax     benefits <font color="blue">usable by us</font> in <font color="blue">previous years</font></td>
    </tr>
    <tr>
      <td>In 2004, we paid dlra13dtta5 million to     <font color="blue">Endo Pharma LLC </font>to satisfy the tax sharing <font color="blue">obligations</font> <font color="blue">attributable</font> to 2001,     2002 and 2003</td>
    </tr>
    <tr>
      <td>Since 6dtta6 million shares underlying <font color="blue">stock option</font>s <font color="blue">granted under</font> the <font color="blue">Endo     </font>Pharma LLC <font color="blue">stock option</font> plans were exercised into <font color="blue">common stock</font> and sold in     the offerings on August 9, 2004 and November 29, 2004, at prices of dlra17dtta46     and dlra20dtta02, respectively, with a <font color="blue">weighted average exercise price</font> of dlra2dtta44,     and an assumed tax rate of 38dtta7prca, we were obligated to pay <font color="blue">Endo Pharma LLC </font>a     tax benefit of <font color="blue">approximately</font> dlra41 million</td>
    </tr>
    <tr>
      <td>Fifty percent of the tax benefit     amount <font color="blue">attributable</font> to these two 2004 offerings and other <font color="blue">Endo Pharma LLC </font>    <font color="blue">stock option</font> exercises in 2004, aggregating dlra21dtta4 million, was due and was     paid within 15 business days of the date we received an <font color="blue">opinion on</font> our     audited 2004 financial statements from our <font color="blue"><font color="blue">independent</font> registered public</font>     <font color="blue">accounting firm</font> and the <font color="blue">remaining fifty percent</font> of the <font color="blue">tax benefit amount</font>     <font color="blue">attributable</font> to 2004 was due within 30 business days of the <font color="blue">date on which</font> we     filed our 2004 tax return with the <font color="blue"><font color="blue">Internal Revenue Service</font> </font>(which occurred     in <font color="blue">September </font>2005) and <font color="blue">approximately</font> dlra21dtta4 million was paid in October 2005     to satisfy the tax sharing <font color="blue">obligations</font> <font color="blue">attributable</font> to 2004</td>
    </tr>
    <tr>
      <td>On October 12, 2005, as part of the sale of 33dtta35 million shares of our     <font color="blue">common stock</font>, <font color="blue">approximately</font> 19dtta5 million shares underlying <font color="blue">stock option</font>s     <font color="blue">granted under</font> the <font color="blue">Endo Pharma LLC </font><font color="blue">stock option</font> plans were <font color="blue">exercised at</font> a     <font color="blue">market price</font> of dlra26dtta04, with a <font color="blue">weighted average exercise price</font> of dlra2dtta72, and     an assumed tax rate of 38dtta4prca</td>
    </tr>
    <tr>
      <td>Since the <font color="blue">attributable</font> <font color="blue"><font color="blue">compensation</font> charge</font>     <font color="blue">deductions</font> are usable to reduce our taxes in 2005, we are obligated, under     our amended tax sharing <font color="blue">agreement</font>, to pay to <font color="blue">Endo Pharma LLC </font>an <font color="blue">additional</font>     <font color="blue">tax benefit amount</font> of <font color="blue">approximately</font> dlra175 million, which has been accrued in     the fourth quarter of 2005</td>
    </tr>
    <tr>
      <td>Fifty percent of the estimated tax benefit     amount <font color="blue">attributable</font> to the October 12, 2005 offering and any <font color="blue">additional</font> tax     benefits <font color="blue">attributable</font> to                                           27     ______________________________________________________________________    [52]Table of <font color="blue">Contents       </font>the exercise of <font color="blue">stock option</font>s <font color="blue">granted under</font> the <font color="blue">Endo Pharma LLC </font><font color="blue">stock option</font>     plans in 2005 will be due within 15 business days of the date we receive an     <font color="blue">opinion on</font> our final audited 2005 financial statements from our <font color="blue">independent</font>     registered public <font color="blue">accounting firm</font> and the remaining <font color="blue">tax benefit amount</font>     <font color="blue">attributable</font> to 2005 is due within 30 business days of the <font color="blue">date on which</font> we     file our 2005 tax return with the <font color="blue">Internal Revenue Service</font></td>
    </tr>
    <tr>
      <td>Additionally, since <font color="blue">approximately</font> 2dtta7 million <font color="blue">additional</font> <font color="blue">stock option</font>s     <font color="blue">granted under</font> the <font color="blue">Endo Pharma LLC </font><font color="blue">stock option</font> plans were <font color="blue">exercised prior</font> to     January 1, 2006 and since the <font color="blue">attributable</font> <font color="blue"><font color="blue">compensation</font> charge</font> <font color="blue">deductions</font>     are usable to reduce our taxes in 2005, we will be obligated, under our     amended tax sharing <font color="blue">agreement</font>, to pay to <font color="blue">Endo Pharma LLC </font>an <font color="blue">additional</font> tax     benefit amount of <font color="blue">approximately</font> dlra26 million in 2006</td>
    </tr>
    <tr>
      <td>As a result of the     <font color="blue">significant</font> tax <font color="blue">deductions</font> expected to have <font color="blue">been generated</font> in 2005 from the     exercise of the 22dtta2 million <font color="blue">stock option</font>s discussed above, we have incurred     a net operating loss in 2005 for <font color="blue">tax purposes which will permit us</font> to obtain     a tax refund of a portion of prior years’ payments during 2006</td>
    </tr>
    <tr>
      <td>All payments     that have been, or will be, made or <font color="blue">accrued pursuant</font> to the tax sharing     <font color="blue">agreement</font> have been, or will be, <font color="blue">reflected as</font> a reduction of <font color="blue">stockholders</font>’     equity in our <font color="blue">consolidated financial statements</font></td>
    </tr>
    <tr>
      <td>As of <font color="blue">December </font>31, 2005,     there are <font color="blue">approximately</font> 2dtta8 million <font color="blue">stock option</font>s remaining to be exercised     under the <font color="blue">Endo Pharma LLC </font><font color="blue">stock option</font> plans</td>
    </tr>
    <tr>
      <td>Using a weighted average     exercise price of dlra2dtta42 per share and an assumed tax rate of 38dtta4prca, if all     of these remaining <font color="blue">stock option</font>s under the <font color="blue">Endo Pharma LLC </font><font color="blue">stock option</font>     plans were vested and exercised, and assuming the price of our <font color="blue">common stock</font>     was dlra30dtta26 per share, the closing price on <font color="blue">December </font>30, 2005, we would     <font color="blue">generally</font>  be able to deduct, for income tax purposes, <font color="blue">compensation</font> of     <font color="blue">approximately</font> dlra78 million, which could result in a <font color="blue">tax benefit amount</font> of     <font color="blue">approximately</font> dlra30 million payable to <font color="blue">Endo Pharma LLC </font>in 2007 and beyond</td>
    </tr>
    <tr>
      <td>Our     <font color="blue">tax sharing <font color="blue">liability</font> as</font> of <font color="blue">December </font>31, 2005 payable to <font color="blue">Endo Pharma LLC </font>is     <font color="blue">approximately</font> dlra195 million</td>
    </tr>
    <tr>
      <td>Although we were successful in our <font color="blue">patent challenge against</font> Purdue for our     generic OxyContin^^®^ product, both at trial and on appeal, the Court of     Appeals has vacated its <font color="blue">unanimous affirmance</font> of the <font color="blue">Opinion and Order </font>in our     favor and affirmed the <font color="blue">District Court</font>’s finding that, if Purdue’s patents     are enforceable, Endo’s <font color="blue">oxycodone extended</font>-release tablets infringe these     patents</td>
    </tr>
    <tr>
      <td>Further, the Federal Circuit issued a <font color="blue">new <font color="blue">opinion on</font></font> <font color="blue">February </font>1,     2006  remanding  the  case  to the same <font color="blue"><font color="blue">District Court</font> </font>for its further     <font color="blue">consideration</font> as to whether <font color="blue">the Purdue </font>patents are unenforceable</td>
    </tr>
    <tr>
      <td>If we are     <font color="blue">ultimately unsuccessful</font>, we may be liable for damages and the price of our     <font color="blue"><font color="blue">common stock</font> may decline</font></td>
    </tr>
    <tr>
      <td><font color="blue">The Purdue Frederick Company </font>and related parties filed suit against us and     our subsidiary, Endo Pharmaceuticals Inc, or EPI, in October 2000 (and     again in March 2001 and August 2001) alleging that our 10mg, 20mg, 40mg and     80mg <font color="blue">bioequivalent</font> versions of OxyContin^^®^, for which we filed an ANDA,     <font color="blue">violate three</font> of their patents</td>
    </tr>
    <tr>
      <td>The US <font color="blue"><font color="blue">District Court</font> </font>for the Southern District of New York     issued an <font color="blue">Opinion and Order </font>on January 5, 2004 holding that, while <font color="blue">Endo     </font>infringes the three Purdue patents, the patents are <font color="blue">unenforceable due</font> to     Purdue’s <font color="blue">inequitable conduct</font></td>
    </tr>
    <tr>
      <td>Accordingly, the district court dismissed     Purdue’s patent <font color="blue">infringement</font> suit against us and EPI, declared the patents     invalid, and enjoined Purdue <font color="blue">from further <font color="blue">enforcement</font></font> of the patents</td>
    </tr>
    <tr>
      <td><font color="blue">Purdue     </font>filed  an appeal as well as motions to stay the <font color="blue">injunction against</font> the     <font color="blue">enforcement</font>  of their <font color="blue">patents pending</font> the outcome of the appeal and to     expedite the appeal</td>
    </tr>
    <tr>
      <td>Both motions were <font color="blue">denied on</font> March 18, 2004</td>
    </tr>
    <tr>
      <td>On June 7,     2005, the US <font color="blue">Court of Appeals </font>for the Federal Circuit in Washington, DC     affirmed the <font color="blue">Opinion and Order </font>of the <font color="blue"><font color="blue">District Court</font> </font>issued in Endo’s favor     on January 5, 2004</td>
    </tr>
    <tr>
      <td>This <font color="blue">affirmance by</font> the <font color="blue">Federal Circuit Court </font>dismissed     the claims that Endo’s <font color="blue">oxycodone extended</font> release tablets infringe <font color="blue">Purdue     </font>patents, and <font color="blue">permanently enjoined</font> Purdue <font color="blue">from enforcing</font> these patents</td>
    </tr>
    <tr>
      <td>On June 21, 2005, Purdue filed a <font color="blue">petition with</font> the <font color="blue">Federal Circuit Court </font>of     Appeals <font color="blue">seeking rehearing</font> of the case by the panel that issued the June 7,     2005 decision, or <font color="blue">alternatively by</font> the <font color="blue">entire court</font></td>
    </tr>
    <tr>
      <td>On July 18, 2005, the     Federal Circuit <font color="blue">Court of Appeals </font>requested that Endo submit a response brief     as  part  of its <font color="blue">review process</font> of Purdue’s petition for rehearing and     rehearing  en banc</td>
    </tr>
    <tr>
      <td>Endo submitted this <font color="blue">response on</font> August 1, 2005</td>
    </tr>
    <tr>
      <td>On     <font color="blue">February </font>1, 2006, we announced that the Federal Circuit <font color="blue">Court of Appeals </font>had     vacated its unanimous June 7, 2005 affirmance of the <font color="blue">Opinion and Order </font>in     our  favor and affirmed the <font color="blue">District Court</font>’s finding that, if Purdue’s     patents are enforceable, Endo’s <font color="blue">oxycodone extended</font>-release tablets infringe     these  patents</td>
    </tr>
    <tr>
      <td>Further,  the Federal Circuit issued a <font color="blue">new <font color="blue">opinion on</font></font>     <font color="blue">February </font>1, 2006 remanding the case to the same <font color="blue"><font color="blue">District Court</font> </font>for its     further <font color="blue">consideration</font> as to whether <font color="blue">the Purdue </font>patents are unenforceable</td>
    </tr>
    <tr>
      <td>We     intend to <font color="blue">continue marketing</font> our generic <font color="blue">oxycodone extended</font>-release tablets     at this time</td>
    </tr>
    <tr>
      <td>In the event there is a final nonappealable judgment that     Purdue’s  patents are valid and enforceable, we could face substantial     <font color="blue">liability</font> for patent <font color="blue">infringement</font> and be obligated to pay Purdue damages in     an amount to be determined by the <font color="blue">District Court</font></td>
    </tr>
    <tr>
      <td>Although there can be no     assurance, we believe that we would be able to fund the payment of these     damages without materially <font color="blue">adversely</font> affecting our business <font color="blue">operations</font>,</td>
    </tr>
  </tbody>
</table>